Compare TG Therapeutics Inc (TGTX) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wolfspeed Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Wolfspeed Inc trades at $31.89 (market cap $1.53B). The key difference: TG Therapeutics Inc is far larger — about 5.4× Wolfspeed Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | WOLF | |
|---|---|---|
Market Cap | $8.26B | $1.53B |
Sector | Health | Technology |
52-Week High | $59.06 | $73.68 |
52-Week Low | $26.39 | $1.19 |
Enterprise Value | $8.50B | $2.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Wolfspeed (WOLF) trades at $29.38, down 1.71% on the day, with a bearish technical outlook driven by moving averages but oversold RSI readings. The company shows negative profitability metrics, including a gross margin of -26.63% and net income margin of -79.83%, though it beat EPS estimates in two of the last three quarters. Recent news highlights strategic moves into data centers and defense, alongside a patent lawsuit against Navitas Semiconductor.
The outlook is mixed, with analyst consensus leaning neutral (47
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
